同步放化疗联合恩度治疗局部中晚期非小细胞肺癌的疗效  

Concurrent Radiotherapy and Chemotherapy Combined with Endostar for Locally Middle and Advanced Non-small Cell Lung Cancer

作　　者：徐辉[1] 秦文娟[1] 郭瑞祥[1] 熊波良 郦守国[1] 侯如蓉[1] 

机构地区：[1]福建省厦门大学附属中山医院,361004

出　　处：《实用癌症杂志》2018年第3期450-453,共4页The Practical Journal of Cancer

摘　　要：目的探讨同步放化疗联合恩度治疗局部中晚期非小细胞肺癌的临床疗效,并观察其对患者生存质量的影响,从而可为临床局部中晚期非小细胞肺癌患者规范、高效治疗提供有力依据。方法按照随机数字表法将78例局部中晚期非小细胞肺癌(腺癌)患者分为对照组(培美曲塞500 mg/m^2,静脉注射15 min,每3周重复1次;同步行放疗)与治疗组(在对照组治疗基础上加恩度15 mg+500 ml 0.9%氯化钠注射液静脉滴注,连续应用14 d,每3周重复1次),各39例。统计两组12个月生存率、中位进展时间及中位生存期;评价两组临床疗效,采用卡氏生活质量(KPS)评分评价两组患者治疗前、后生存质量,并记录治疗期间不良反应。结果治疗组患者12个月生存率为92.31%,明显高于对照组(71.79%),P<0.05;中位进展时间、中位生存期分别为(7.85±1.27)个月、(9.98±1.71)个月,明显高于对照组(6.07±0.98)个月、(7.99±1.38)个月,P<0.05。治疗组总有效率为76.92%,明显高于对照组(48.72%),P<0.05;治疗组与对照组治疗后KPS评分分别为(73.17±2.75)分、(59.68±2.52)分,明显高于治疗前(52.75±2.02)分、(53.01±1.98)分,且治疗组KPS评分明显高于对照组,P<0.05。治疗组不良反应发生率(43.59%)与对照组(48.72%)相比,P=0.64。结论辅以恩度治疗中晚期非小细胞肺癌可有利于提高临床疗效及患者生存期,更好的改善其生存质量,且不会增加不良反应,因此值得推荐。Objective To investigate the efficacy of concurrent radiotherapy and chemotherapy combined with endostar for locally middle and advanced non-small cell lung cancer and to observe its effect on the quality of life of the patients, thus providing a powerful basis for standard and effective treatment of patients with locally middle and advanced non-small cell lung cancer. Methods 78 patients with locally middle and advanced non-small cell lung cancer （adenocarcinoma） were divided into the control group （pemetrexed 500 mg/m^2 ,intravenous injection for 15 min,every 3 days） ,and the treatment group （15 mg ＋ 500 ml 0.9% sodium chloride injection for 14 days,repeated once every 3 weeks）,each with 39 eases. 12-month survival rate,the median time to progression and the median survival time of the 2 groups were evaluated. The clinical efficacy was evaluated by KPS. The quality of life before and after treatment were evaluated and the duration of treatment reaction. Results 12-month survival rate of the treatment group was 92.31% , which was significantly higher than the control group ,71.79% , P 〈 0. 05. The median progression time and median survival time of the treatment group were （7.85 ±1.27 ） months, （9.98 ± 1.71 ） months ,which were significantly higher than the control group（6.07 ±0.98） months, （7.99 ± 1.38） months,P 〈0.05. The total effective rate was 76.92% in the treatment group and 48.72% in the control group （P 〈 0.05）. The KPS scores of the treatment group and the control group were （ 73. 17 ±2.75 ）, （ 59.68 ± 2.52 ） after treatment, which were significantly higher than before treatment （52.75 ±2.02） and （53. 01 ±0. 98） ,and the KPS score of the treatment group was significantly higher than that of the control group （P 〈0.05）. The adverse reaction rate was 43.59% in the treatment group and 48.72% in the control grouP,χ^2 =0.20,P = 0.64. Conclusion Combined with endostar treatmentfor advanced non-small cell lung cancer can help improve clin

关 键 词：中晚期非小细胞肺癌 恩度 培美曲塞 生存质量 化疗 

分 类 号：R734.2[医药卫生—肿瘤]